Stockscreener 앱 받기
108.50
1.63%
-1.795
시간 외 거래:
108.50
전일 마감가:
$110.30
열려 있는:
$108.65
하루 거래량:
478.11K
Relative Volume:
0.39
시가총액:
$6.72B
수익:
$3.99B
순이익/손실:
$463.16M
주가수익비율:
15.28
EPS:
7.1
순현금흐름:
$1.10B
1주 성능:
-2.37%
1개월 성능:
+5.43%
6개월 성능:
-11.82%
1년 성능:
-3.73%
1일 변동 폭
$108.02
$110.04
1주일 범위
$108.02
$114.30
52주 변동 폭
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
JAZZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
108.50 | 6.72B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Autistic Disorder Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Biosciences - Barchart.com
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav® - Insider Monkey
Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®. - Yahoo Finance
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals (JAZZ) Stock Ratings Reiterated by Needham - GuruFocus
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Jazz Pharmaceuticals at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Nigeria
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - marketscreener.com
Transcript : Jazz Pharmaceuticals plcSpecial Call - marketscreener.com
Jazz Pharmaceuticals Says Zepzelca-Tecentriq Combination Gets FDA Priority Review for Lung Cancer Treatment - marketscreener.com
FDA Fast-Tracks Jazz Pharmaceuticals' Lung Cancer Drug Application - GuruFocus
Jazz Pharma stock gains on FDA review for lung cancer therapy - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Awaits FDA Decision on Lung Cancer Treatment | JAZZ Stock News - GuruFocus
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer - PR Newswire
Jazz Pharmaceuticals Says Narcolepsy Drug Meets Primary Endpoint in Phase 4 Trial - marketscreener.com
Parallel Advisors LLC Acquires 119 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz Pharmaceuticals (JAZZ) Reveals New Findings on Xywav at SLEEP 2025 | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcas - GuruFocus
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 - PR Newswire
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - marketscreener.com
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? - Yahoo Finance
May 2026 Options Now Available For Jazz Pharmaceuticals - Nasdaq
Needham Says Promising Data Underscore Growth Potential for Jazz Pharma (JAZZ) - MSN
Insider Sell: Bruce Cozadd Sells Shares of Jazz Pharmaceuticals PLC - GuruFocus
Jazz Pharmaceuticals plc (JAZZ)’s Zepzelca Combo Boosts Survival in ES-SCLC - MSN
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Given “Buy” Rating at Needham & Company LLC - Defense World
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer StudyJazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
UBS maintains buy rating on Jazz Pharmaceuticals stock after positive trial data - Investing.com Nigeria
Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment - MSN
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts - Benzinga
Jazz Pharmaceuticals (JAZZ) Maintains Buy Rating with $202 Price Target | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Reports Positive Results for Zepzelc - GuruFocus
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Resu - GuruFocus
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination - marketscreener.com
Jazz Pharmaceuticals (JAZZ) Reveals Promising Phase 3 Trial Results for Zepzelca | JAZZ Stock News - GuruFocus
Zepzelca combo extends survival in lung cancer study - Investing.com
Phase 3 Trial: Zepzelca Combo Cuts Lung Cancer Progression Risk by 46% | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals (JAZZ) Reports Promising Long-term Data for Ziihera | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Says Ziihera Achieves Over 3 Years Median Overall Survival in Gastroesophageal Cancer - marketscreener.com
Jazz Pharmaceuticals reports promising Phase 2 trial results for Ziihera - Investing.com
Jazz Pharmaceuticals (JAZZ) Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera in mGEA - StreetInsider
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 - PR Newswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire Inc.
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals Reveals 19 New Xywav Studies for Sleep Disorders at SLEEP 2025 | JAZZ Stock News - Stock Titan
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG - Defense World
Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Idiopathic Hypersomnia Treatment Market: Drug Pipeline, - openPR.com
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jazz Pharmaceuticals Plc 주식 (JAZZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | Chairman & CEO |
Jun 02 '25 |
Sale |
107.90 |
500 |
53,950 |
438,473 |
1.91%
1.17%
자본화:
|
볼륨(24시간):